Enhanced T-Cell Expression of RANK Ligand in Acute Coronary Syndrome
- 1 April 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 26 (4) , 857-863
- https://doi.org/10.1161/01.atv.0000204334.48195.6a
Abstract
Objective— Based on its role in inflammation and matrix degradation, we hypothesized a role for osteoprotegerin (OPG), RANK, and RANK ligand (RANKL) in coronary artery disease. Methods and Results—... We show enhanced expression of osteoprotegerin (OPG), RANK, and RANK ligand (RANKL) in clinical and experimental atherosclerosis with enhanced T-cell expression of RANKL as an important feature of ...Keywords
This publication has 23 references indexed in Scilit:
- Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factorCytokine, 2005
- Dysregulated Osteoprotegerin/RANK Ligand/RANK Axis in Clinical and Experimental Heart FailureCirculation, 2005
- Osteoprotegerin and Osteopontin Are Expressed at High Concentrations Within Symptomatic Carotid AtherosclerosisStroke, 2004
- Disruption of TGF-β signaling in T cells accelerates atherosclerosisJournal of Clinical Investigation, 2003
- Biology of the TRANCE axisCytokine & Growth Factor Reviews, 2003
- Inflammation in atherosclerosisNature, 2002
- Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biologyJournal of Molecular Medicine, 2001
- Effects of Immunosuppressants on Receptor Activator of NF-κB Ligand and Osteoprotegerin Production by Human Osteoblastic and Coronary Artery Smooth Muscle CellsBiochemical and Biophysical Research Communications, 2001
- Osteoprotegerin Is an αvβ3-induced, NF-κB-dependent Survival Factor for Endothelial CellsJournal of Biological Chemistry, 2000
- Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors.The Journal of Experimental Medicine, 1992